| [1] |
Bahadoram S, Davoodi M, Hassanzadeh S, et al. Renal cell carcinoma: an overview of the epidemiology, diagnosis, and treatment[J]. G Ital Nefrol, 2022, 39(3): 2022-vol3.
|
| [2] |
Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European association of urology guidelines on renal cell carcinoma: the 2019 update[J]. Eur Urol, 2019, 75(5): 799-810.
|
| [3] |
Makino T, Kadomoto S, Izumi K, et al. Epidemiology and prevention of renal cell carcinoma[J]. Cancers, 2022, 14(16): 4059.
|
| [4] |
Govindarajan A, Castro DV, Zengin ZB, et al. Front-line therapy for metastatic renal cell carcinoma: a perspective on the current algorithm and future directions[J]. Cancers, 2022, 14(9): 2049.
|
| [5] |
Iaxx R, Lefort F, Domblides C, et al. An evaluation of cabozantinib for the treatment of renal cell carcinoma: focus on patient selection and perspectives[J]. Ther Clin Risk Manag, 2022, 18: 619-632.
|
| [6] |
周东杰, 蒋敏, 范海瑞, 等. 非编码RNA在卵泡发育成熟中作用及其机制的研究现状[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(4): 387-393.
|
| [7] |
Chi Y, Wang D, Wang J, et al. Long non-coding RNA in the pathogenesis of cancers[J]. Cells, 2019, 8(9): 1015.
|
| [8] |
Li M, Jiao L, Shao Y, et al. LncRNA-ZFAS1 promotes myocardial ischemia-reperfusion injury through DNA methylation-mediated Notch1 down-regulation in mice[J]. JACC Basic Transl Sci, 2022, 7(9): 880-895.
|
| [9] |
Wang J, Liu Z, Xu Y, et al. Enterobacterial LPS-inducible LINC00152 is regulated by histone lactylation and promotes cancer cells invasion and migration[J]. Front Cell Infect Microbiol, 2022, 12: 913815.
|
| [10] |
Zhou C, Wang D, Li J, et al. TGFB2-AS1 inhibits triple-negative breast cancer progression via interaction with SMARCA4 and regulating its targets TGFB2 and SOX2[J]. Proc Natl Acad Sci USA, 2022, 119(39): e2117988119.
|
| [11] |
Zhou J, Xu N, Liu B, et al. lncRNA XLOC013218 promotes cell proliferation and TMZ resistance by targeting the PIK3R2-mediated PI3K/AKT pathway in glioma[J]. Cancer Sci, 2022, 113(8): 2681-2692.
|
| [12] |
Zhang F, Wang H, Yu J, et al. LncRNA CRNDE attenuates chemoresistance in gastric cancer via SRSF6-regulated alternative splicing of PICALM[J]. Mol Cancer, 2021, 20(1): 6.
|
| [13] |
Zhang Y, Luo M, Cui X, et al. Long noncoding RNA NEAT1 promotes ferroptosis by modulating the miR-362-3p/MIOX axis as a ceRNA[J]. Cell Death Differ, 2022, 29(9): 1850-1863.
|
| [14] |
Wu R, Hu W, Chen H, et al. A novel human long noncoding RNA SCDAL promotes angiogenesis through SNF5-mediated GDF6 expression[J]. Adv Sci, 2021, 8(18): e2004629.
|
| [15] |
Li Z, Ma Z, Xu X. Long non-coding RNA MALAT1 correlates with cell viability and mobility by targeting miR-22-3p in renal cell carcinoma via the PI3K/Akt pathway[J]. Oncol Rep, 2019, 41(2): 1113-1121.
|
| [16] |
Zhang H, Li W, Gu W, et al. MALAT1 accelerates the development and progression of renal cell carcinoma by decreasing the expression of miR-203 and promoting the expression of BIRC5[J]. Cell Prolif, 2019, 52(5): e12640.
|
| [17] |
Pu Y, Dong Z, Xia Y, et al. LncRNA NONHSAT113026 represses renal cell carcinoma tumorigenesis through interacting with NF-κB/p50 and SLUG[J]. Biomed Pharmacother, 2019, 118: 109382.
|
| [18] |
Feng JF, Wang J, Xie G, et al. KMT2B promotes the growth of renal cell carcinoma via upregulation of SNHG12 expression and promotion of CEP55 transcription[J]. Cancer Cell Int, 2022, 22(1): 197.
|
| [19] |
Zhang C, Ren X, Zhang W, et al. Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers[J]. Bioengineered, 2020, 11(1): 1112-1123.
|
| [20] |
Ren Y, Huang W, Weng G, et al. LncRNA PVT1 promotes proliferation, invasion and epithelial-mesenchymal transition of renal cell carcinoma cells through downregulation of miR-16-5p[J]. Onco Targets Ther, 2019, 12: 2563-2575.
|
| [21] |
Ramadoss S, Chen X, Wang CY. Histone demethylase KDM6B promotes epithelial-mesenchymal transition[J]. J Biol Chem, 2012, 287(53): 44508-44517.
|
| [22] |
Xia M, Yao L, Zhang Q, et al. Long noncoding RNA HOTAIR promotes metastasis of renal cell carcinoma by up-regulating histone H3K27 demethylase JMJD3[J]. Oncotarget, 2017, 8(12): 19795-19802.
|
| [23] |
Gong A, Zhao X, Pan Y, et al. The lncRNA MEG3 mediates renal cell cancer progression by regulating ST3Gal1 transcription and EGFR sialylation[J]. J Cell Sci, 2020, 133(16): jcs244020.
|
| [24] |
Troiani M, Colucci M, D’Ambrosio M, et al. Single-cell transcriptomics identifies Mcl-1 as a target for senolytic therapy in cancer[J]. Nat Commun, 2022, 13(1): 2177.
|
| [25] |
Wu Q, Yang F, Yang Z, et al. Long noncoding RNA PVT1 inhibits renal cancer cell apoptosis by up-regulating Mcl-1[J]. Oncotarget, 2017, 8(60): 101865-101875.
|
| [26] |
Jiang Y, Li W, Yan Y, et al. LINC01094 triggers radio-resistance in clear cell renal cell carcinoma via miR-577/CHEK2/FOXM1 axis[J]. Cancer Cell Int, 2020, 20: 274.
|
| [27] |
Song E L, Xing L, Wang L, et al. LncRNA ADAMTS9-AS2 inhibits cell proliferation and decreases chemoresistance in clear cell renal cell carcinoma via the miR-27a-3p/FOXO1 axis[J]. Aging, 2019, 11(15): 5705-5725.
|
| [28] |
Barth DA, Drula R, Ott L, et al. Circulating non-coding RNAs in renal cell carcinoma-pathogenesis and potential implications as clinical biomarkers[J]. Front Cell Dev Biol, 2020, 8: 828.
|
| [29] |
Wu Y, Wang YQ, Weng WW, et al. A serum-circulating long noncoding RNA signature can discriminate between patients with clear cell renal cell carcinoma and healthy controls[J]. Oncogenesis, 2016, 5(2): e192.
|
| [30] |
He ZH, Qin XH, Zhang XL, et al. Long noncoding RNA GIHCG is a potential diagnostic and prognostic biomarker and therapeutic target for renal cell carcinoma[J]. Eur Rev Med Pharmacol Sci, 2018, 22(1):46-54.
|
| [31] |
Xie J, Zhong Y, Chen R, et al. Serum long non-coding RNA LINC00887 as a potential biomarker for diagnosis of renal cell carcinoma[J]. FEBS Open Bio, 2020, 10(9): 1802-1809.
|
| [32] |
Qu L, Ding J, Chen C, et al. Exosome-transmitted lncARSR promotes sunitinib resistance in renal cancer by acting as a competing endogenous RNA[J]. Cancer Cell, 2016, 29(5): 653-668.
|
| [33] |
Pan Y, Lu X, Shu G, et al. Extracellular vesicle-mediated transfer of LncRNA IGFL2-AS1 confers sunitinib resistance in renal cell carcinoma[J]. Cancer Res, 2023, 83(1): 103-116.
|
| [34] |
Tang H, Chen H, Yuan H, et al. Comprehensive analysis of necroptosis-related long noncoding RNA to predict prognosis, immune status, and immunotherapeutic response in clear cell renal cell carcinoma[J]. Transl Cancer Res, 2022, 11(12): 4254-4271.
|
| [35] |
Zhou L, Fang H, Guo F, et al. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma[J]. J Clin Lab Anal, 2022, 36(8): e24582.
|
| [36] |
Pang Y, Wang Y, Zhou X, et al. Cuproptosis-related LncRNA-based prediction of the prognosis and immunotherapy response in papillary renal cell carcinoma[J]. Int J Mol Sci, 2023, 24(2): 1464.
|